PF-06873600是具有口服活性的、细胞周期蛋白依赖性激酶(CDK)的选择性抑制剂，其对CDK2、CDK4和CDK6的Ki值分别为0.09nM、0.13nM和0.16nM.PF-06873600具有潜在的抗肿瘤活性。
CAS：2185857-97-8
分子式：C20H27F2N5O4S
分子量：471.52
纯度：98%
存储：Store at -20°C

Background:

PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase (CDK), with Ki values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively. PF-06873600 has potential antineoplastic activity[1][2].

PF-06873600 (Example 8) is an orally bioavailable, cyclin-dependent kinase (CDK) inhibitor, with potential antineoplastic activity[1]. PF-06873600 selectively targets, binds to and inhibits the activity of CDKs. Inhibition of these kinases leads to cell cycle arrest, induction of apoptosis and inhibition of tumor cell proliferation. CDKs, ATP-dependent serine/threonine kinases that are important regulators of cell cycle progression and cellular proliferation, are frequently overexpressed in tumor cells[2].

[1]. US 2018/0044344 A1. [2]. NCI Drug Dictionary